Carbohydrate ‘cage’ allows precise drug delivery to the gastrointestinal tract

More Canadians suffer from inflammatory bowel disease (IBD) than anywhere else in the world, yet current treatments often have debilitating side effects and are not always effective.

GlycoNet researchers from the University of British Columbia, BC Children’s Hospital, and Agriculture and Agri-Food Canada, are challenging the status quo as they develop a technology that they termed “GlycoCage.” This technology is aimed to improve the efficacy of IBD drugs by refining the method of drug delivery to patients. READ MORE